Abstract Inhibitor of apoptosis proteins (IAPs) are critical in regulating apoptosis resistance in cancer. Antagonists of IAPs, such as LCL161, are in clinical development and show promise as anti-cancer agents for solid and hematological cancers, with preliminary data suggesting they may act as immunomodulators. IAP antagonists hypersensitize tumor cells to TNF-a-mediated apoptosis, an effect that may work in synergy with that of cancer vaccines. This study aimed to further investigate the immunomodulatory properties of LCL161 on human immune subsets. T lymphocytes treated with LCL161 demonstrated significantly enhanced cytokine secretion upon activation, with little effect on CD4 and CD8 T-cell survival or proliferation. LCL161 treatment of peripheral blood mononuclear cells significantly enhanced priming of naïve T cells with synthetic peptides in vitro. Myeloid dendritic cells underwent phenotypic maturation upon IAP antagonism and demonstrated a reduced capacity to cross-present a tumor antigen-based vaccine. These effects are potentially mediated through an observed activation of the canonical and non-canonical NF-jB pathways, following IAP antagonism with a resulting upregulation of anti-apoptotic molecules. In conclusion, this study demonstrated the immunomodulatory properties of antagonists at physiologically relevant concentrations and indicates their combination with immunotherapy requires further investigation.
Introduction
Following a long period with little clinical success, immunotherapy is finally delivering on decades of promise. Recently, two immune-based therapies have demonstrated significant clinical benefit [1, 2] . However, for future success with immune therapies such as therapeutic cancer vaccines, significant hurdles still need to be overcome. Where successful therapies may emerge is through the combination of targeted small molecule agents and immunotherapy, to transiently reduce tumor growth and survival while creating a permissive environment for the enhancement of immunotherapy. However, given that many of the targeted molecules are critically involved in the survival and function of immune cells, a careful evaluation is required to understand potential 'off-target' effects of these agents on immune cells [3, 4] .
An attractive class of small molecule agents are antagonists of the inhibitor of apoptosis proteins (IAPs). The IAP family of proteins has diverse roles in regulating apoptosis, acting as regulators of caspase activation and through control of NF-jB signaling. IAPs are regulated by the second mitochondrial activator of caspases (SMAC)/ DIABLO [5, 6] , and synthetic small molecule mimetics of SMAC (IAP antagonists) demonstrate potent anti-cancer activity [7, 8] . Although originally hypothesized to mediate tumor apoptosis through direct caspase activation, IAP antagonists have been shown to function through the autoubiquitination and degradation of cIAPs. This results in the activation of the canonical and non-canonical NF-jB signaling pathways, leading to production of TNF-a and, in the absence of cIAPs, apoptosis induction through the consequent autocrine and paracrine TNF receptor signaling [9] [10] [11] . In addition, IAP antagonists may sensitize tumor cells to FAS and TRAIL-mediated apoptosis [12] [13] [14] [15] . Therefore, the combination of an anti-cancer vaccine with an agent able to potentiate the activity of immune effector cells is a promising strategy. Successful combination of IAP antagonists with immune therapy will depend on potential off-target effects. A number of studies have demonstrated a role for IAPs in leukocyte biology. cIAPs form part of a multi-protein complex regulating CD40 signaling [16, 17] and survival and responsiveness [18] in B lymphocytes. They are involved in Toll-like receptor signaling in macrophages [19] and the differentiation of monocytes into macrophages [20] , the protection of macrophages from apoptosis following lipopolysaccharide (LPS) stimulation [21] , and the protection of CD8? T cells from apoptosis during human T-cell leukemia virus type 1 (HTLV-1 infection) [22, 23] . A recent report demonstrated that IAP antagonists mediate co-stimulation to promote anti-tumor immunity [24] . In that study, IAP antagonists were shown to augment murine lymphocyte proliferation, functioning through the activation of NF-jB2, and to potentiate antitumor vaccines in vivo using a B16 mouse melanoma model.
In this study, we investigate the immunomodulatory properties of the IAP antagonist LCL161 on human immune subsets and effects that may influence its combination with immune therapies. This orally administered IAP antagonist has been shown to be well tolerated in cancer patients in a phase I study with no associated doselimiting toxicities [25] . We demonstrate that at the clinically achievable concentrations, IAP antagonists have little direct effect on lymphocyte viability or proliferation, but significantly increase the cytokine secretion by effector and helper T cells and enhance the in vitro expansion of antigen-specific naïve and memory T cells. Finally, we demonstrate that IAP antagonism results in the phenotypic maturation of human dendritic cells, with an associated activation of the canonical and non-canonical NF-jB pathways and a reduction in the capacity to cross-present a cancer vaccine.
Methods
Reagents IAP antagonists (IAP-As) LBW242 and LCL161 [25] [26] [27] were kindly provided by Novartis Pharma Ag and solubilized in 100 % DMSO at 10 mM. All phenotyping antibodies were from BD Biosciences, unless indicated otherwise. NY-ESO-1-specific CD8? T-cell clones were generated with synthetic peptides as previously described [28] . Complete media contain RPMI 1640 with 20 mM HEPES, 60 mg/l penicillin, 12.5 mg/l streptomycin, 2 mM L-glutamine, 1 % non-essential amino acids and 10 % heatinactivated fetal calf serum (Gibco). All flow cytometry was performed on a BD FACS Canto II, and data analyses were performed using the FlowJo software (TreeStar Inc).
Lymphocyte functional assays

Viability
T cells were isolated with MACS positive selection (Miltenyi Biotech) ([96 % purity), un-stimulated/stimulated with microbeads coated with anti-CD3/CD28 antibodies (Invitrogen) at a 2:1 ratio, with or without the indicated concentration of IAP antagonist for the indicated time in complete media. Viability was assessed using antiannexin V-FITC and propidium iodide (Sigma). To evaluate viability, both Ann-V?/PI? and Ann-V?/PI-cells were classified as apoptotic. Cells were analyzed by flow cytometry.
Proliferation assay
Purified CD4 and CD8 T cells were labeled with 1 lM CFSE (Invitrogen), plated at 5 9 10 4 /well and stimulated as above. After staining with anti-CD3, anti-CD4 and anti-CD8, cells were analyzed on the BD FACSCanto II, gating for lymphocytes with FSC/SSC parameters. Data analysis was performed using FlowJo and the included Proliferation tool. The 'Proliferation index' was used to define a proliferation value. This value, which represents the average number of cell divisions undergone by the responding cells, more faithfully reflects the biology of the system by considering only the fraction of responding cells (http://www. flowjo.com/v7/html/proliferation.html).
Cytokine production assay
Purified CD4 and CD8 T cells were plated at 1 9 10 5 cells/ well and stimulated as above. After 20, 40 and 68 h, GolgiPlug (BD Bioscience) was added for the final 4 h to halt cytokine secretion. Cells were stained with anti-CD3, anti-CD4 and anti-CD8 antibodies, permeabilized (Fix/ Perm kit, BD) and stained for IFN-gamma (eBioscience). Cells were analyzed by flow cytometry.
Peptide stimulation assay
Healthy donor peripheral blood mononuclear cells (PBMCs) were plated at 1 9 10 6 cells/well in complete media with 1 lg/ml (final concentration) synthetic peptides. HLA-A2-restricted epitopes Flu-M1,58-66; BMLF1,280-288 and Melan-A,26-35 (all synthesized Mimotopes, Australia) were added with or without IAP antagonist. After 24 h, 25 IU IL-2 (Proleukin Ò ) was added, and subsequently every 3 days till day 10. Then, PE-conjugated HLA-A2 tetramers containing the relevant peptide (Tetramer Production Facility, LICR, Lausanne, Switzerland) were used to evaluate the percentage of specific CD8? CD3? T cells. Cells were analyzed by flow cytometry.
Dendritic cell culture
PBMCs from healthy donor buffy coats (Red Cross Blood Bank, Melbourne, Australia) were prepared by FicollPaque density gradient centrifugation (GE Healthcare). Monocytes were isolated with anti-CD14 microbeads to a purity [95 % (Miltenyi Biotech). Immature monocytederived dendritic cells (imoDCs) were generated from monocytes with GM-CSF (20 ng/ml) and IL-4 (10 ng/ml) for 4-5 days. Where indicated, imoDCs were treated with titrating concentrations of IAP antagonist or 500 ng/ml CD40L-trimer (a kind gift from Amgen, CA, USA) for 24 or 48 h. Phenotypic analysis was performed using the following antibodies: anti-annexin V, anti B7-DC, anti B7-H1, anti B7-1, anti B7-2 anti HLA-DR, and anti CD14 in combination with a violet live/dead fluorescent viability dye (Invitrogen). Cells were analyzed by flow cytometry.
Tumor antigen cross-presentation assay
ImoDCs were plated at 1 9 10 5 cells/well in 96 well U-form plate in 200 ll fresh culture media supplemented with GM-CSF. Where indicated, imoDCs were treated with titrating concentrations of IAP antagonist or 500 ng/ml CD40L-trimer for 24 or 48 h before pulsing with antigen. DCs plated in culture media were then pulsed with recombinant NY-ESO-1/ISCOMATRIX vaccine formulation (as previously described [29] ) for 18 h with or without the IAP antagonist, as indicated. DCs were then washed and used as targets for NY-ESO-1-specific CD8? T-cell clones and T-cell activation measured by intracellular cytokine staining (ICS). T cells were added at[1:10 effector-to-target ratio with GolgiPlug for 4 h, stained for CD3 and CD8, then permeabilized and stained for IFN-gamma. Cells were analyzed by flow cytometry. Where indicated, prior to the ICS assessment, DCs were pulsed for 1 h with 10 lg/ml of the NY-ESO-1 157-165 peptide followed by washing.
Endocytosis assay
This assay was a modification of a published protocol [30] . Briefly, 1 lM Fluoresbrite Ò yellow green carboxylated latex microspheres (Polysciences, Inc.) were coated overnight with 1 mg/ml mouse IgG (ES121 antibody, LICR Melbourne) or BSA (Sigma). ImoDCs were plated at 1 9 10 5 cells/well in 96 wells in fresh culture media supplemented with GM-CSF and where indicated with IAP antagonist at 10 lM. After 24 h, DCs were pulsed with 9.1 9 10 7 coated beads/mL at 37°C for 45 min and washed. Cells were analyzed on a BD FACS Canto II, and data analyses were performed using FlowJo. As a control, PHA-activated, purified CD4 T cells were also pulsed for 45 min at 378 C to control for non-specific cell adhesion versus endocytosis.
Immunoblotting
Cells were lysed in RIPA buffer (Sigma-Aldrich) supplemented with protease inhibitor cocktail (Roche) and for anti-phospho antibody analysis with PhosSTOP (Roche). SDS-PAGE analyses were performed using 4-12 % NU-PAGE gels (Invitrogen). Membranes were blocked with 5 % BSA/TBS (dilutant for antibodies plus 0.1 % Tween 20). All primary antibodies were used at 1:1,000 overnight at 4°C. They are the following: anti-Bcl-xL (54H6), antiIjBalpha (44D4), anti-phospho Rel-A (93H1), anti-p52/ p100 (18D10), anti-cIAP1 (R.pAb) and cIAP-2 (58C7) (Cell Signaling Technology) and anti-b-tubulin/b-actin (Sigma-Aldrich). For anti-IjBalpha stains, a peroxidaselabeled anti-rabbit immunoglobulin (Sigma) secondary antibody was used at 1:20,000 dilution, and bands were visualized using chemiluminescence (ECL Plus) using a STORM imager (GE Healthcare). For all other blots, Ir-dye secondary antibodies were used at 1:15,000-1:25,000 dilution, and membranes were imaged on an Odyssey Imager (LI-COR Biosciences). Quantification was performed using the incorporated Odyssey Software.
Quantitative RT-PCR
qRT-PCR was performed with a Stratagene Mx3005 (Stratagene). RNA isolation was undertaken using the RNeasy kit (Qiagen). cDNA was prepared using the ABI High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems) with random primers and RNA purified from control or drug-treated imoDC as indicated. qPCR was performed using the indicated primers, designed to span across intron/exon boundaries using the primer design software from Roche and verified using BLAST. QuantiFast SybrGreen MasterMix was used according to the manufacturer's protocol. Expression was calculated as transcript numbers of the gene of interest per b-actin transcript using (2 (bactin CT-gene of interest CT) ).
Multiplex cytokine/chemokine analysis
MoDCs were plated at 100,000 cells per well in 200 ll of media in a 96-well plate and treated with 10 lM of drug for 48 h. Cell-free supernatants were collected and frozen at -80°C for further analysis. The samples were diluted, acquired and analyzed using a Luminex200 plate reader and Xponent Version 3.1 software, respectively. Standard curves contained 7 points, ranging from 0.64, 3.2, 16, 80, 400, 2,000 to 10,000 pg/ml for the indicated cytokines/ chemokines. Sample concentrations were calculated based on the standard curve with a 4-parameter logistic analysis and Y weighted as 1/Y^2. TNF-alpha ELISA was performed on supernatants using the BD OptEIA human TNF ELISA set (BD Bioscience) according to the manufacturer's protocol.
Results
The IAP antagonist, LCL161, enhances T-lymphocyte cytokine secretion but has a negligible effect on proliferation and apoptosis induction Degradation of IAPs by small molecule inhibitors has been shown to induce apoptosis in solid [9, 10] and hematopoietic tumor cells [27, 31] . To explore whether the investigational IAP antagonist (IAP-A), LCL161, exhibited any effects on human lymphocytes, we assessed apoptosis induction, cell proliferation and cytokine secretion in CD8? and CD4? T cells with and without T-cell activation. The production of TNF-a and IL-2 was studied in purified CD4? and CD8? T cells following non-specific activation with anti-CD3/CD28 beads in the presence of titrating concentrations of LCL161 (0.1, 1.0 and 10 lM). ICS was performed on T cells 24, 48 and 72 h post-treatment/activation. A concentration-dependent increase in cytokine production was observed upon drug treatment and TCR stimulation, with a significant increase in the frequency of cytokine-producing cells demonstrated at the 10 lM concentration (P \ 0.05); an example of IL-2 production in CD4? T cells from 3 donors is shown (Fig. 1a) , and representative ICS data for IL-2 and TNF-a are shown (Online resource Figure 5 ). However, due to large interdonor variation in the percentage of cytokine-producing cells following activation (in the absence of drug), fold increase in percentage of cytokine-producing cells (with drug) versus the untreated control was determined, thus normalizing the response for effect of the IAP-A. Treatment with LCL161 results in a significant and concentrationdependent increase in the number of TNF-a and IL-2-producing T cells following the activation at all time points (except for IL-2 production by CD8? T cells at 24 h) (P \ 0.05) (Fig. 1b) . The largest effect was an increase in IL-2-producing cells 72 h following activation. No significant cytokine secretion was detected in T cells following drug treatment in the absence of cellular activation via the T-cell receptor (data not shown).
To assess viability and apoptosis induction, purified CD4? and CD8? T cells were unstimulated or nonspecifically activated in the presence of titrating concentrations of LCL161 (0.1, 1.0 and 10 lM). Apoptosis induction was assessed 24, 48 and 72 h following treatment. Although overall modest, the largest effect observed was for unstimulated CD8? T cells at 24 h with an increase in the mean percentage of apoptotic cells of just 11 % at 10 lM LCL161. For all conditions excepting activated CD8? T cells, a small but statistically significant increase (P \ 0.05) in apoptosis induction was observed with 10 lM LCL161 at the 24-and 48-h time points (Online Resource Figure 1A ). To investigate the effects of the investigational drug on lymphocyte proliferation, purified CD4? and CD8? T cells were labeled with the membrane-incorporating dye CFSE to track cellular divisions and left unstimulated or activated in the presence of titrating concentrations of LCL161 or an analogue IAP-A compound, LBW242, described to modulate murine lymphocyte proliferation [24] . After 96 h, proliferation was assessed and a proliferation index for each treatment condition and population was determined (detailed in Materials and Methods). No proliferation was observed for either population in the absence of activation with or without IAP antagonist treatment (data not shown). Representative proliferation plots for activated CD8? T cells are shown (Online Resource Figure 1B) . No significant effect was observed at any concentration of LCL161 or LBW242, although a trend for a concentration-dependent decrease in proliferation following treatment with inhibitors for both T-cell subsets was observed (Online Resource Figure 1C ). Taken together, these data demonstrate that treatment of human T lymphocytes with IAP antagonists increases the frequency and duration of cytokine production in CD4 and CD8 T cells while having negligible effects on lymphocyte proliferation and viability. Without concurrent T-cell activation, IAP-As have little effect on T lymphocytes for the parameters studied. IAP antagonism enhances the stimulation of antigen-specific T lymphocytes
To investigate the effect of IAP-As on lymphocyte activation, in vitro peptide stimulation experiments were performed using antigens that would stimulate both memory and naïve CD8? T cells in whole PBMC cultures. Immunodominant epitopes from the influenza matrix antigen and the EBV BMLF1 protein were selected to stimulate memory responses. Melan-A, a melanocyte differentiation antigen, was shown to a high precursor frequency of naïve CD8? T cells in healthy donors [32] . Healthy donor PBMCs were stimulated in vitro with each of these peptides in the presence of titrating concentrations of LCL161 (0, 0.1, 1.0 and 10 lM), and the frequency of specific CD8? T cells was assessed using recombinant MHC tetramers. A concentration-dependent increase in the frequency of antigen-specific T cells was observed for all peptides; tetramer staining is shown for a representative donor for each epitope (Fig. 2a) . The greatest effect was observed with the Melan-A peptide at 10 lm LCL161 (mean, 3.8 %; n = 6) in which the smallest amplification was observed following peptide stimulation without drug (mean, 0.26 %; n = 6), thus representing a 15-fold increase in specific cells with drug addition. A summary of the mean response in multiple donor PBMC for Flu-M1, BMLF1 and Melan-A demonstrates a statistically significant increase in the frequencies of expanding BMLF-1-and Melan-A-specific cells at 10 lM LCL161 treatment (Fig. 2b) . No statistically significant increase for the Flu-M1 epitope was observed, to which a large frequency of responding cells was detected in the absence of drug (mean, 23.5 %; n = 5). A trend for increase in response magnitude was observed, however, with the greatest effect at the 1 lM concentration (33.2 %, n = 5). These data are contradictory to the results obtained in the short-term proliferation assays employing a strong, non-specific TCR stimulus, where the IAP-As had minimal or even negative effect on T-cell proliferation. The peptide stimulation results may reflect a difference in the response to the IAPAs that is dependent on the strength of the T-cell receptor signal received by the T cell or the degree and breadth of co-stimulatory signals received. Therefore, the results may have been influenced by IAP-As acting on other cell subsets within the culture, such as antigen-presenting cells.
IAP antagonists promote dendritic cell maturation
IAPs have been described to play a number of roles that influence myeloid cell biology, partially resulting from the ubiquitin ligase activity of the members cIAP1 and cIAP2. Studies have demonstrated a role for cIAP1/2 in Toll-like receptor (TLR) signaling by regulating MyD88-dependent activation in murine macrophages [19] . Dupoux et al. [20] have demonstrated that cIAP1-dependent degradation of TRAF2 regulates the differentiation of monocytes into macrophages. These studies imply that IAP-As may have significant effects on inflammatory APCs, such as moDC, which may represent an important population for vaccine biology [29, 33, 34] . Therefore, maturation of immature moDCs (imoDC) was evaluated as a result of IAP-A treatment. In vitro differentiated moDCs were treated with titrating concentrations of LCL161 (0, 0.1, 1.0 and 10 lM) for 24 and 48 h. Viability and phenotypic markers of maturation were assessed by flow cytometry. Soluble CD40L was employed as a comparator for the induction of maturation. Following 4-day differentiation and a further 24-to 48-h culture without treatment, imoDC upregulated annexin V and started to undergo apoptosis. Treatment with sCD40L abrogated surface expression of annexin V (P \ 0.001), protecting the cells from apoptosis. This effect was paralleled by the action of LCL161, with 10 lM LCL161 at 48 h significantly decreasing annexin V expression (P \ 0.01) (Fig. 3a) . To address the effect of LCL161 on maturation, expression of co-stimulatory molecules of the B7 family (B7-1, B7-2, of B7-H1 [PD-L1] and B7-DC [PD-L2]) on imoDC was measured following treatment. The greatest effect was observed with upregulation of B7-DC in a time-and concentration-dependent manner (48 h, 10 lM: P \ 0.001) (Fig. 3b) . No significant upregulation of B7-H1 was observed with treatment (data not shown). B7-1 was also significantly upregulated as a result of LCL161 treatment (P \ 0.05) (Fig. 3c ). B7-2 and HLA-DR were expressed on *100 % of imoDC at all drug concentrations; thus, changes in molecule density were measured by FACS. A significant increase in both molecules was observed at 48 h post-treatment (P \ 0.01) (Fig. 3d, e) . Representative flow cytometry stains are shown for donor 1 at the 48-h time point (Online resource Figure 6 ). Taken together, these data indicate that IAP antagonists protect immature DC from apoptosis and promote maturation, similar to the results observed with CD40L stimulation.
Induction of NF-jB signaling and expression of anti-apoptotic molecules mediated by IAP-A treatment of dendritic cells IAP-As have been shown to result in the auto-ubiquitination and degradation of cIAPs in tumor cells, where loss of cIAPs results in activation of both the canonical and noncanonical NF-jB signaling pathways leading to production of TNF-a [11] . Given the importance of NF-jB signaling in DC biology for the expression of pro-inflammatory cytokines [35] and that CD40 signals through both the canonical and non-canonical NF-jB pathways [36] , we investigated whether either pathway is modulated in moDC as a result of IAP-A exposure. In the canonical pathway, stimulation leads to the activation of the IjB kinase (IKK) complex and degradation of IjB proteins. Expression of IjBa in imoDCs was monitored by Western blot analysis at four time points following treatment with 10 lM LCL161 (Fig. 4a, b) . A significant loss of IjBa occurred at the 6-and 24-h time points following treatment (P \ 0.001; Fig. 4a, b) . Degradation of IjB proteins was followed by p65 (RelA) phosphorylation, which was assessed after treatment with 10 lM LCL161. Phosphorylation was detectable above the untreated control level at 2, 6 and 24 h following treatment. CD40L served as a positive control with phospho-p65 detectable at 30 min (not shown) and 24 h after stimulation (P \ 0.001) (Fig. 4c, d ). Although not reaching statistical significance, a mean 2.5-fold increase in phospho-p65 was detected 24 h following drug treatment. However, LCL161-induced activation was lower in magnitude than that observed with CD40 ligation (Fig. 4c, d ). To investigate the activation of the noncanonical pathway, we assessed degradation of p100 to p52; an event mediated by NIK and the IKK complex. Drug-induced degradation of p100 and a reciprocal p52 expression were observed 24 h post-LCL161 treatment, with CD40L inducing the greatest p52 levels (P \ 0.05) (Fig. 4e, f) . A ratio of p52 to p100 levels shows a significant increase at 24 h following LCL161 (P \ 0.01) and with CD40L (P \ 0.05) (Fig. 4e, f) . Taken together, these data support our hypothesis that IAP antagonism leads to the activation of the canonical and non-canonical NF-jB pathways in human APC. NF-jB signaling controls the expression of anti-apoptotic molecules, including members of the Bcl-2 family [37] , and has also been described to regulate expression of IAP molecules [21] . Therefore, we assessed the expression of cIAP1/ 2, Bcl-2 and Bcl-xL in LCL161-treated imoDC by qPCR and Western blot analysis. qRT-PCR analysis showed no significant change in cIAP1 expression with either LCL161 or CD40L, whereas CD40L (P \ 0.001) and LCL161 (P \ 0.05) significantly increased the expression of cIAP2. A time-dependant increase in Bcl-2 expression was observed, although only reaching statistical significance with CD40L (P \ 0.001). Bcl-xL expression was significantly increased (P \ 0.05 and P \ 0.001) following LCL161 and CD40L treatment, respectively (Fig. 5a) . Western blot analysis of cIAP2 confirmed LCL161-mediated degradation up to 2 h following treatment with a recovery of expression at 6 h and an increase in protein levels at 24 h (Fig. 5b) . Bcl-xL protein levels showed a modest increase at 24 h (Fig. 5c ). CD40L induced a significant increase in expression of both proteins at 24 h (P \ 0.001). The induced expression of anti-apoptotic factors is consistent with the observed survival and loss of annexin V expression levels and activation of NF-jB following treatment with LCL161. To assess the functional effects of IAP antagonists on DC biology, cytokine secretion and antigen cross-presentation were evaluated in vitro. TNF-a ELISAs were performed on the culture media of imoDC treated for 24, 48 and 72 h with titrating concentrations of LCL161. Soluble CD40L stimulation served as a positive control. Although significant quantities of TNF-a were detectable following CD40L stimulation, no TNF-a was found following treatment with LCL161 at any concentration, suggesting that IAP-A treatment of immature DC does not activate TNF-a secretion (data not shown). Furthermore, supernatants from 48 h cultures were assessed for 8 cytokines/chemokines using multiplex technology following LCL161 treatment alone or in combination with CD40L. Again, no induction of any factor (IL-1b, -6, -8, 10, 12p70, TNF-a, MIP-1a, MIP-1b) was observed with treatment, although MIP-1b levels decreased relative to the untreated cells. Interestingly, LCL161 treatment of CD40L-activated moDC also showed a trend for a slight reduction in levels for three cytokine/chemokines at 48 h, although significance was not achieved and donor variability was significant (Online Resource Figure 2 ). These data demonstrate that the NFjB signaling observed in LCL161-treated imoDC does not result in the induction of pro-inflammatory cytokines, even though phenotypical maturation is observed. If IAP antagonists are to be employed in combination with therapeutic cancer vaccination, it is critical to understand their potential effect on a DC's capacity to process and present antigen. Therefore, we studied the effect of IAP-A treatment on cross-presentation of the previously reported cancer vaccine, NY-ESO-1/ISCOMATRIX (ESO/ IMX) [29, 38, 39] . ImoDCs were untreated or treated with the IAP antagonist for 24 or 48 h and pulsed with the ESO/ IMX vaccine for a further 18 h to allow uptake, antigen processing and presentation. Cross-presentation of the HLA-A2-restricted epitope 157-165 by the antigen-pulsed DC was assessed using an epitope-specific CD8? T-cell clone. Recognition assays measured specific IFN-c production in a short-term co-culture experiment. No drug was present in this assay to influence the T-cell function. In a representative example, LCL161 treatment prior to ESO/ IMX pulsing of DC resulted in a concentration-dependent reduction in the recognition of DC by the specific T-cell clone, corresponding to an *50 % reduction in responding cells at 10 lM LCL161 (Fig. 6a ). Due to a large interdonor variation in percentage response in the untreated control, for each donor, the treatment values were normalized against the untreated control value and thus response is expressed as an activation index. This enabled the assessment of the drug effect on recognition of the epitope. Treatment with CD40L prior to antigen loading resulted in a significant mean reduction in recognition by the specific clone of *40 % at the 24-and 48-h time points (P \ 0.001) (Fig. 6b) . LCL161 treatment prior to antigen exposure also resulted in a time-and concentrationdependent reduction in recognition by the epitope-specific T-cell clone. A significant reduction in the mean value was observed at 24 and 48 h (P \ 0.05 and P \ 0.001, respectively). At 48 h after 10 lM LCL161 treatment, a reduction in magnitude equivalent to that of CD40L treatment was observed. LBW242, the less active analogue compound, resulted in smaller effect than that observed with LCL161, with significance only observed 48 h following treatment (P \ 0.05) (Fig. 6b) .
A hallmark of DC maturation is the reduced capacity for antigen endocytosis when compared to immature DC, associated with an increased capacity for antigen processing and presentation [40, 41] . Given our data, which demonstrated that IAP antagonists induce a phenotypic maturation of imoDC, the observed reduction in recognition by the epitopespecific T-cell clone may be due to the reduced capacity for treated DCs to uptake the ESO/IMX complex. Endocytosis assays [30] were performed on IAP-A-treated imoDC, using 1-lm fluorescent latex particles coated in BSA or immunoglobulin. Endocytosis was measured by flow cytometry to quantitate bead-containing cells. No drug-dependent reduction in the endocytosis capacity of treated imoDC was observed in repeated assays (Online Resource Figure 3) .
Interestingly, concurrent treatment of imoDC with the ESO/IMX complex and LCL161 for just 18 h also resulted in a significant decrease in recognition of DC by the NY-ESO-1-specific T cells (P \ 0.001) (Online Resource Figure 4 ). The ESO/IMX vaccine has been demonstrated to be rapidly endocytosed, processed and resulted in the presentation of NY-ESO-1 epitopes within fewer than 6 h in vitro [42] . Our data indicated that full phenotypic maturation of DCs induced by LCL161 required 24-48 h. Together, these pieces of evidence suggest that it is unlikely that the reduced recognition in the presence of LCL161 was a result of reduced antigen uptake through maturation, given the kinetics of the experiment. Importantly, IAP-A-treated DCs loaded exogenously with synthetic peptide show no reduction in their capacity to stimulate specific T cells, suggesting that the IAP-A effects are also associated with antigen processing and presentation (Online Resource Figure 4A ).
Discussion
In this study, we sought to address the potential of IAP antagonists to modulate human immune cells with a view to their combination with immunotherapy for cancer. Our data indicate that an IAP-A in clinical development, LCL161, positively impacted on T-lymphocyte function with regard to enhanced cytokine production; specifically TNF-alpha, a know potentiator of tumor cell apoptosis in the presence of IAP-As. The compound demonstrated little effect on human lymphocyte viability. IAP antagonist treatment of moDC resulted in protection from apoptosis, similar to that observed with CD40 ligation. NF-jB signaling is shown to result in the upregulation of anti-apoptotic factors [37] , and canonical NF-jB signaling has been reported to be required for protection from apoptosis and to ensure cell survival in developing and differentiated moDC [43] . Loss of cIAPs has been reported to result in the Fig. 6 IAP antagonists significantly decrease cross-presentation of tumor antigen by monocyte-derived dendritic cells. MoDCs plated in triplicate were treated for 24 or 48 h with titrating concentrations of LCL161 or LBW242, and rNY-ESO-1/ISCOMATRIX was added for an additional 18 h following treatment. An antigen-specific CD8? T-cell clone was used to assess cross-presentation of MHCclass I-associated epitopes in a standard recognition assay measuring specific cytokine secretion by the T cells upon activation. a An NY-ESO-1-specific (157-165/HLA-A2) CD8? T-cell clone was incubated for 4 h with the previously treated and antigen-pulsed DC, and the percentage of activated, IFN-c-positive CD8? CD3? cells (y-axis) within the lymphocyte FACS gate (x-axis) was assessed at each drug concentration used to treat the moDC (indicated above contour plots). b All values were normalized against the untreated control to compensate for inter-donor variation in the % IFN-c? cells responding within the untreated group, and therefore allowing assessment of drug effect. This value is referred to as an 'activation index' (y-axis) and indicates relative activation (IFN-c positivity) of the specific T-cell clone following a 4-h incubation with the 24-or 48-h drug-treated and antigen-pulsed DC at the concentration indicated (x-axis) for LCL161 (upper scatter plots) and LBW242 (lower scatter plots). Each point represents the mean from triplicate results per donor, per concentration with the grand mean (horizontal bar) and SEM shown from 4 donors. One-way ANOVA with a Dunnett's post-test against the untreated control was performed, *P \ 0.05, ***P \ 0.001 accumulation of NIK and activation of the alternative NFjB pathways in other cell types [9, 10] , and indeed, we observed concurrent activation of NF-jB signaling in moDC following treatment with LCL161, a transient loss and then recovery of cIAP2 and further upregulation of anti-apoptotic molecules. Regulation of cIAP via NF-jB signaling has been previously described in myeloid cells, where by LPS signaling upregulates cIAP2 in macrophages [21] , and thus is a possible explanation for our observed results. However, the LCL161-induced loss of cIAP2 and its subsequent recovery (as seen on the mRNA and protein level) may have been the result of a feedback loop following the transient drop in protein levels and thus independent of the NF-jB signaling concurrently induced by the IAP antagonists. Further studies are required to elucidate this direct connection as observed in mDC.
NF-jB signaling is critical in dendritic cell biology [35, 36] , where the capacity of CD40 ligation to regulate myeloid DC function is driven by the non-canonical NF-jB pathway [44] , and blockade of NF-jB can result in the induction of tolerogenic DCs [45, 46] . However, contradictory data exist for the role of NF-jB signaling in the regulation of co-stimulatory molecules by myeloid DC [43, 47, 48] . We obtained clear evidence for the upregulation of co-stimulatory molecules of the B7 family as well as HLA-DR following IAP antagonism in the absence of additional maturation factors and concurrent activation of NF-jB signaling. Although direct mechanistic evidence is not provided in this study, given the described activation of the signaling pathway by IAP degradation and the importance of the pathway in DC maturation, our data support a role for NF-jB signaling in phenotypic maturation in this setting. An increase in co-stimulatory molecule expression on DC by IAP antagonism would be complementary to the importance of IAPs in regulating signaling down-stream from TNF family co-stimulatory molecules on T lymphocytes [24] , giving IAP antagonists the capacity to greatly enhance priming of naïve T cells reliant on co-stimulatory signals. This would offer an explanation to support the observed enhancement of in vitro priming of naïve T cells in our study. Interestingly, we did not observe the induction of pro-inflammatory cytokines in DC classically associated with NF-jB activation. Of note, a study investigating the role of cIAP1/2 in TLR signaling demonstrated that treatment of murine bone marrow-derived macrophages with an IAP antagonist targeting these molecules resulted in the inhibition of pro-inflammatory cytokines production following TLR4 signaling without preventing NF-jB activation or the IFN response [19] .
A recent report describes the combination of an IAP-A with cancer vaccines in a murine model of melanoma, resulting in enhanced vaccine efficacy in vivo [24] . We investigated the effect of IAP-As on a cancer vaccine comprising recombinant NY-ESO-1 protein and the adjuvant ISOMATRIX [29, 34, 38, 42] , in an in vitro human system. We demonstrate that IAP antagonist treatment of human myeloid dendritic cells, prior to antigen exposure or concurrently, results in a reduced capacity to activate antigen-specific T cells when cross-presenting the ESO/ IMX vaccine. Dendritic cell maturation has been associated with a decrease in the capacity to uptake and process antigen [41] , although potentially not for all forms of antigen [30] . Our results from endocytosis experiments did not indicate that prior IAP antagonist treatment of immature moDC had an effect on particle uptake. However, the kinetics of maturation parallel the level and kinetics of reduced cross-presentation, and therefore, it seems likely that the lower activation of T cells is a result of reduced antigen uptake through maturation. Differences in particle sizes may account for the experimental discrepancy. Of note is the reduced cross-presentation observed with concurrent IAP-A treatment and antigen exposure for a reduced time period. The previously described rapid kinetics of ISCOMATRIX-mediated antigen uptake, proteasome-independent processing and presentation of NY-ESO-1 epitopes [29, 49] would suggest this process happens before the maturation effects of the IAP-A would take place; also before the observed NF-jB signaling would have occurred. The precise mechanism warrants further investigation.
In conclusion, although the data from this study support the combination of IAP antagonists with a number of immunotherapeutic approaches-based on the enhancement of lymphocyte function, maturation of moDC and enhancement in the activation and expansion of antigenspecific T cells-for combination with protein-based cancer vaccines, the treatment schedule for vaccination and LCL161 administration may have to be carefully considered. Together with the capacity to enhance T-cell-mediated secretion of TNF-a, highly beneficial considering IAP antagonists hypersensitize tumor cells to TNF-mediated apoptosis, IAP antagonists should be investigated further as a novel class of immunomodulators for combination with tumor immunotherapy.
